The small-molecule MERTK inhibitor UNC2025 decreases platelet activation and prevents thrombosis. J Thromb Haemost 2018; 16: 352-63.
Essentials
• Signaling by Gas6 through Tyro3/Axl/Mer receptors is essential for stable platelet aggregation.
• UNC2025 is a small molecule inhibitor of the Mer tyrosine kinase.
• UNC2025 decreases platelet activation in vitro and thrombus formation in vivo. • UNC2025's anti-platelet effect is synergistic with inhibition of the ADP receptor, P2Y 12 .
Summary. Background: Growth arrest-specific protein 6 signals through the TAM (TYRO-3-AXL-MERTK) receptor family, mediating platelet activation and thrombus formation via activation of the aggregate-stabilizing a IIb b 3 integrin. Objective: To describe the antithrombotic effects mediated by UNC2025, a small-molecule MERTK tyrosine kinase inhibitor. Methods: MERTK phosphorylation and downstream signaling were assessed by immunoblotting. Light transmission aggregometry, flow cytometry and microfluidic analysis were used to evaluate the impact of MERTK inhibition on platelet activation and stability of aggregates in vitro. The effects of MERTK inhibition on arterial and venous thrombosis, platelet accumulation at microvascular injury sites and tail bleeding times were determined with murine models. The effects of combined treatment with ADP-P2Y 1&12 pathway antagonists and UNC2025 were also evaluated. Results and Conclusions: Treatment with UNC2025 inhibited MERTK phosphorylation and downstream activation of AKT and SRC, decreased platelet activation, and protected animals from pulmonary embolism and arterial thrombosis without increasing bleeding times. The antiplatelet effect of UNC2025 was enhanced in combination with ADP-P2Y 1&12 pathway antagonists, and a greater than additive effect was observed when these two agents with different mechanisms of inhibition were coadministered. TAM kinase signaling represents a potential therapeutic target, as inhibition of this axis, especially in combination with ADP-P2Y pathway antagonism, mediates decreased platelet activation, aggregate stability, and thrombus formation, with less hemorrhagic potential than current treatment strategies. The data presented here also demonstrate antithrombotic activity mediated by UNC2025, a novel
Introduction
Stable platelet aggregation is essential for adequate hemostasis, but uncontrolled platelet activation may lead to life-threatening thromboses such as arterial ischemic stroke or myocardial infarction. Current antiplatelet therapies are complicated by hemorrhagic side effects and interpatient response variability [1] , demonstrating the need to explore new pathways that may yield safer and more effective therapies. Extracellular growth arrest-specific protein 6 (GAS6) stimulates the platelet surface TYRO-3-AXL-MERTK (TAM) family of transmembrane receptor tyrosine kinases [2] [3] [4] [5] [6] to dimerize and autophosphorylate [7] [8] [9] , activating phosphatidylinositol 3-kinase (PI3K) [10, 11] , RAP1 [11] [12] [13] , and AKT [14, 15] , thereby triggering b 3 integrin phosphorylation and amplifying outside-in signaling [2, 16, 17] . GAS6 has been reported in human platelets and plasma [3, 5, 18] , and bridges membrane-bound phosphatidylserine [19, 20] and TAM kinases [21, 22] .
Inhibition or absence of GAS6 or any TAM receptor decreases platelet aggregation and impairs thrombus formation [2, 3, 23, 24] . Gas6 À/À mice form unstable platelet aggregates that are stabilized by the addition of recombinant human GAS6 [5] . GAS6 enhances PI3K phosphorylation in platelets from wild-type mice, but not in platelets from Tyro3
Interestingly, absence of GAS6-TAM signaling does not increase spontaneous hemorrhage or bleeding time after tail clipping [2-4, 6,25] . Here, we describe a novel mechanism of GAS6-TAM signal inhibition in platelets, targeting the MERTK tyrosine kinase active site with a highly potent and bioavailable MERTK inhibitor, UNC2025 [26] [27] [28] [29] .
Materials and methods

Platelet activation inhibitors
1 UNC2025: MERTK inhibitor synthesized as described [26] . The molecular structure is shown in Fig. S1 . In some cases, MRS2179 and 2-MeSAMP were used together, and are collectively referred to as P2Y receptor inhibitor (P2Yi).
Blood collection
Human whole blood (WB) was collected by venipuncture from healthy volunteers after informed consent had been obtained under an Institutional Review Board-approved protocol.
Washed platelet (WP) and platelet-rich plasma (PRP) preparation WB was drawn from healthy volunteers into 3.8% sodium citrate, with addition of acid-citrate-dextrose [30, 31] . WPs and PRP were prepared as described previously [32] .
Platelet aggregation
Human WPs or PRP, or murine WPs, were incubated for 15 min with saline (vehicle), 0.5 lM (WPs) or 5 lM (PRP) UNC2025, 0.001 lM PBS0739 (P2Y 12 receptor inhibitor), or 2 lM abciximab (positive control). Samples were analyzed by light transmission aggregometry after stimulation with 1 lg mL À1 (WPs) or 2 lg mL À1 (PRP) collagen, 50 ng mL À1 convulxin, 2 lM ADP, or 1 U mL À1 thrombin. Maximum aggregation (%) was recorded.
Flow cytometry
Human WPs were incubated for 15 min with saline (vehicle), 0.5 lM UNC2025, or 2 lM abciximab, and then stimulated with 50 ng mL À1 convulxin (Santa Cruz Biotechnology, Santa Cruz, CA, USA). PAC-1 antibodies (BD Biosciences, San Jose, CA, USA) were added immediately after convulxin, samples were incubated for 5 min, and platelets were fixed with 2% paraformaldehyde (Sigma-Aldrich). Samples were analyzed with a Gallios flow cytometer (Beckman-Coulter, Indianapolis, IN, USA). Mean fluorescence intensity was recorded.
Microfluidic flow assay
Microfluidic experiments were performed on a collagen surface [33] [34] [35] . WB (100 lL) was incubated for 1 min with saline (vehicle), 1 lM UNC2025, or 2 lM abciximab (positive control), and then pulled through the channels for 3 min at a physiologic wall shear rate (650 s À1 ). Platelet adhesion and aggregation were captured in real time with an ORCA Flash4 CMOS camera (Orca-ER; Hamamatsu, Hamamatsu City, Japan) and CELLSENSE imaging software (Olympus Life Science, Center Valley, PA, USA), with images being acquired every 1 s over the duration of the experiment. Surface area coverage and aggregate size were determined for each series. Murine models All experiments were approved by university animal care and use committees, and involved equal numbers of 6-12-week-old male and female C57BL/ 6J mice (Jackson Laboratories, Bar Harbor, ME, USA). Mice were anesthetized and subjected to endotracheal intubation and mechanical ventilation [36] [37] [38] [39] ) were then administered, and time to breathing cessation was recorded as described previously [24, 38] . Mice that remained alive 15 min after collagen/epinephrine administration were killed, and experimental time was recorded as 15 min.
Intravital microvascular thrombosis
Mice underwent intravital microscopy of the cremaster muscle microcirculation [40, 41] . Arterioles 30-40 lm in diameter with unperturbed blood flow were studied. After a 10-min stabilization period, labeled anti-CD41 F(ab) 2 fragments (0.12 lg g À1 body weight), anti-P-selectin (0.2 lg g
À1
) and anti-fibrin (0.2 lg g À1 ) were intravenously infused. Vascular injury was induced by pulsed nitrogen dye laser (NL100, 440 nm; Stanford Research Systems, Sunnyvale, CA, USA), and up to five injuries and thrombi were recorded in each mouse following saline infusion. Next, 3 mg kg À1 UNC2025 was infused and allowed to circulate for 30 min, and a second set of injuries/thrombi were recorded. CD41, P-selectin and fibrin were measured by summing all pixels in a frame with the corresponding fluorescence intensity above background. or UNC2025 + LD P2Yi was injected into the retro-orbital sinus and allowed to circulate for 15 min. Tails were snipped 1 cm from the tip, and the proximal ends were placed in a conical tube containing 37°C normal saline for 15 min. Total bleeding time (including rebleeds) was recorded [37, 38] .
Synergy calculations
Median effect analysis was performed according to the methods of Chou and Talaly [42] with Calcusyn software (Calcusyn, Cambridge, UK). Interactions were also assessed with the Bliss additivity equation Fa 12 = fa 1 + fa 2 -fa 1 9 fa 2 , where fa = frequency of effect mediated by drug 1 or 2, respectively, and Fa 12 = predicted frequency of effect for an additive interaction. An observed Fa greater than the calculated Fa 12 indicates synergy.
Statistical analyses
Data with a Gaussian distribution are expressed as mean AE standard error of the mean (SEM), with significance evaluated with paired, two-tailed t-tests. Data with a non-normal non-Gaussian distribution are expressed as median AE interquartile range (IQR), and were evaluated with Mann-Whitney rank sum tests. Experiments with human WB, PRP or WPs were performed and analyzed as paired samples. Murine assays were analyzed as unpaired samples.
Results
UNC2025 decreased platelet MERTK phosphorylation and downstream signaling
UNC2025 caused dose-dependent inhibition of MERTK phosphorylation in unstimulated human platelets and after stimulation with collagen ( Fig. 1A) . In this context, treatment with 0.5 lM UNC2025 resulted in partial inhibition of MERTK, and a dose of 5 lM was sufficient for more complete inhibition. Signaling through the AKT and SRC pathways, which are known downstream targets of MERTK, was similarly descreased in platelets treated with UNC2025 (Fig. 1B ). These data demonstrate the utility of UNC2025 as a MERTK inhibitor in human platelets, and define the dose of UNC2025 required for effective MERTK inhibition.
UNC2025 decreased human and murine platelet activation
UNC2025 caused dose-dependent decreases in mean (AE SEM) maximum aggregation of human platelets stimulated with collagen, ADP, or thrombin (Fig 2A,B ; Fig. S2 ). Treatment with 0.5 lM UNC2025 decreased mean (AE SEM) maximum collagen-stimulated aggregation of human WPs (18.0% AE 9.8%, n = 6, P < 0.05) as compared with saline-treated controls (54.0% AE 8.7%, n = 6) ( Fig. 2A) . Similarly, Fig. 2B demonstrates decreased collagen-stimulated aggregation of human PRP pretreated with 5 lM UNC2025 (36.9% AE 12.0%, n = 7, P < 0.05) as compared with saline-treated controls (75.7% AE 8.7%, n = 7). Pretreatment with 2 lM abciximab is shown as a positive control. Finally, treatment with 0.5 lM UNC2025 also caused decreased collagen-stimulated aggregation of murine WPs (37.3% AE 5.7%, n = 10, p < 0.01) as compared with saline-treated controls (58.2% AE 5.8%, n = 20) (Fig. S3 ).
As both GAS6-TAM and ADP-P2Y signaling axes involve PI3K-mediated activation of integrin a IIb b 3 , we next studied the nature of platelet inhibition and thrombosis protection after antagonism of both of these pathways. Treatment with 0.5 lM UNC2025 or 0.001 lM PBS0739, a P2Y 12 inhibitor, caused decreased collageninduced aggregation of human WPs, and the effect of combined treatment was more than additive, according to analyses with both the Chou-Talaly and Bliss independence models ( Fig. 2C; Fig. S4 ). The mean maximum collagen-induced aggregation in samples treated with 0.5 lM UNC2025 (55.0% AE 1.7%, n = 6, P < 0.001) or 0.001 lM PBS0739 (64.1% AE 2.3%, n = 6, P < 0.05) differed significantly from that in saline-treated negative controls (70.3% AE 1.2%, n = 6). Samples treated with a combination of PBS0739 and UNC2025 had significantly decreased mean maximum aggregation (38.3% AE 4.4%, n = 6) as compared with samples treated with saline (P < 0.001), UNC2025 alone (P = 0.006), or PBS0739 alone (P = 0.002). The combination index was determined on the basis of the Chou-Talaly model, and was < 1, indicating synergy [42] . According to the Bliss additivity equation, a mean (AE SEM) 31% AE 7.2% decrease in platelet aggregation was predicted for an additive interaction, but significantly greater inhibition (61% AE 8.8%, P = 0.02) was observed, indicating synergistic inhibition of platelet aggregation mediated by the two compounds.
UNC2025 decreases activation of a IIb b 3
Next, we studied the effects of UNC2025 on activation of human WPs as indicated by P-selectin expression (anti-Pselectin antibody binding) and conformational change of b 3 integrin (PAC-1 binding). Samples treated with 0.5 lM UNC2025 showed decreased mean fluorescence intensity (AE standard error) of PAC-1 binding (respectively: 1.3 AE 0.3 units, P < 0.005; and 0.16 AE 0.03 units, P < 0.01) as compared with controls pretreated with an equivalent volume of saline (1.9 AE 0.26 units, n = 5) (Fig. 2D ).
There was no significant difference in P-selectin expression ( Fig. S5 ) between groups. The lack of changes in anti-P-selectin antibody binding suggests that a-granule release was not affected by treatment with UNC2025.
UNC2025 reduced human platelet aggregate stability under flow conditions
The impact of UNC2025-mediated MERTK inhibition on platelet aggregate formation in human WB was evaluated under physiologic flow conditions, with a microfluidic model [35, 43] . At the end of each WB perfusion (and buffer rinse), platelet aggregates showed decreased surface area coverage in samples treated with 0.5 lM UNC2025 as compared with saline-treated samples (Fig. 3A,B) . The surface area covered by platelet aggregates increased over time in all samples, but the increase was more pronounced after saline treatment than after treatment with UNC2025 or abciximab. Smaller aggregates were observed at the end of the run in UNC2025-treated samples, and disaggregation of large aggregates was directly visualized during the run and occurred more often in UNC2025-treated samples than in saline-treated samples. Review of the surface area coverage accumulation over time revealed a trend towards greater mean (AE standard error) numbers of aggregate embolizations under flow conditions in samples pretreated with UNC2025 (8.1 AE 3.2) than in controls pretreated with saline, although this difference did not reach statistical significance (4.0 AE 0.9, P = not significant [NS]). Mean (AE standard error) surface area coverage at the end of the run (after buffer rinse) was significantly decreased in
4 pixels, n = 5, P < 0.05), as seen in Fig. 3C . Thus, MERTK inhibition decreased platelet aggregate stability under flow conditions.
After 300 s, samples pretreated with UNC2025 showed a decreased area under the curve ([12.5 AE 1.5] 9 10 4 pixels) as compared with saline-treated controls ([37.4 AE 2.8] 9 10 4 pixels), and the area under the curve was similar to that of samples pretreated with the positive control abciximab ([2.6 AE 0.2] 9 10 4 pixels) (Fig. 3D ).
UNC2025 decreased platelet activation at murine microcirculation vascular injury sites (Fig. 4) . Video S1A and Video S1B show the increase in total and activated platelet accumulation at the injury site in saline-treated controls as compared with UNC2025-treated mice, respectively.
UNC2025 decreased murine arterial thrombosis
Next, we evaluated the effects of UNC2025 on larger vessels. Mice pretreated with 3 mg kg À1 UNC2025 30 min prior to 6% FeCl 3 application to the carotid artery showed prolonged time to initial clot formation (Fig. 5A ) and decreased thrombus stability (Fig. 5B) as compared with saline-treated controls. Mean (AE SEM) TTFO in saline-treated controls (7.3 AE 0.3 min, n = 19) was significantly shorter than that in mice treated with UNC2025 (8.4 AE 0.6 min, n = 10, P = 0.05) (Fig. 5A ). Median DOO, defined as the total time of vessel occlusion during a 60-min experiment, was significantly longer in salinetreated controls (52.3 min, IQR 47.8-53.3 min, n = 19) than in UNC2025-treated mice (38.2 min, IQR 9.9-50.1 min, n = 10, P = 0.02) (Fig. 5B ). These results demonstrate that UNC2025-mediated protection of mice from arterial clots is probably attributable, at least in part, to decreased stability of the initial platelet aggregate. Review of the ultrasound probe tracings revealed a trend towards increased mean (AE standard error) clot embolizations in mice pretreated with UNC2025 (2.1 AE 1.0 emboli per mouse) as compared with controls pretreated with saline (0.9 AE 0.5 emboli per mouse, P = NS).
GAS6-TAM inhibition decreased fatal murine pulmonary embolism
Similarly, we evaluated the effects of UNC2025 in a collagen/epinephrine-induced PE model. Median survival time of saline-treated controls (2.5 min, IQR 2.0-3.1 min, n = 27) was shorter than that of mice treated with 3 mg kg À1 UNC2025 (15 min, IQR 1.6-15 min, n = 16, P < 0.001) (Fig. 5C ). Fifty-six per cent of UNC2025-treated mice were alive 15 min after collagen/epinephrine injection, whereas all saline-treated controls developed fatal emboli in < 5 min. These data demonstrate UNC2025-mediated protection of mice from PE.
UNC2025 did not increase murine tail bleeding times
Significant differences in median bleeding times were not observed between saline-treated controls (6.2 min, IQR 5.9-8.5 min, n = 8) and mice treated with 3 mg kg À1 UNC2025 (5.9 min, IQR 4.8-8.5 min, n = 3) (Fig. 5D ).
Combined antagonism of GAS6-TAM and ADP-P2Y 12 allows for inhibitor dose reduction in vivo
Similarly to the synergistic inhibition of platelet activation observed in aggregation assays, combined antagonism of P2Y and MERTK decreased thrombus formation in vivo.
In the arterial thrombosis model, longer TTFO (Fig. 5A ) was observed in mice treated with HD P2Yi (8.8 AE 0.6 min, n = 5, P < 0.05) or 3 mg kg À1 UNC2025 (8.4 AE 0.6 min, n = 10, P < 0.05) alone than in salinetreated controls (7.3 AE 0.6 min, n = 19). LD P2Yi-treated mice showed TTFO similar that of saline-treated controls (7.5 AE 0.2 min, n = 5, P = NS). Combining UNC2025 and the subtherapeutic LD P2Yi (9.9 AE 0.4 min, n = 5, P < 0.05), however, recapitulated the significantly longer TTFO caused by HD P2Yi. Similarly, shorter DOO (Fig. 5B) In the PE model (Fig. 5C ) prolonged median survival was observed following collagen/epinephrine injection in mice treated with HD P2Yi (15.0 min, IQR 2.9-15.0 min, n = 12, P < 0.001) or UNC2025 (15.0 min, IQR 1.6-15.0 min, n = 16, P < 0.001) as compared with salinetreated controls (2.5 min, IQR 2.0-4.2 min, n = 27). Median survival was not significantly different in LD P2Yi-treated mice (6.9 min, IQR 2.2-15.0 min, n = 5), but treatment with the combination of UNC2025 and LD P2Yi (15.0 min, IQR 15.0-15.0 min, n = 6, P < 0.0001) recapitulated the longer survival caused by HD P2Yi. Sixty-eight per cent of HD P2Yi-treated mice (P < 0.001), 40% of LD P2Yi-treated mice (P = NS), 56% of UNC2025-treated mice (P < 0.001), and 90% of LD P2Yi + UNC2025-treated mice (P < 0.0001) were alive 15 min after collagen/epinephrine administration, whereas all saline-treated controls developed fatal emboli within 5 min. These data indicate that adding UNC2025 allows P2Yi dose reduction in murine models without compromising protection from arterial or venous thrombosis.
Mean (AE SEM) tail bleeding times (Fig. 5D ) were similar in mice pretreated with vehicle (6.4 AE 0.9 min, n = 8), UNC2025 (6.0 AE 1.2 min, n = 3, P = NS), LD P2Yi (6.5 AE 2.0 min, n = 3, P = NS), or LD P2Yi combined with UNC2025 (6.6 AE 2.7 min, n = 3, P = NS). Only HD P2Yi (12.9 AE 2.1 min, n = 3, P < 0.05) significantly prolonged bleeding.
Discussion
We show herein that pharmacologic inhibition of GAS6-TAM signaling efficiently abrogated platelet activation responses, leading to decreased aggregate stability and reduced thrombosis in animal models without increased bleeding. Additionally, we demonstrated a synergistic antiplatelet effect in the context of ADP-P2Y inhibition, consistent with a previous report suggesting that interruption of a IIb b 3 activation decreases the stability of platelet aggregates [44] . UNC2025 had antithrombotic and direct antiplatelet activity in a variety of in vitro and in vivo assays, both alone and in combination with P2Y inhibitors. UNC2025-treated platelets showed decreased activation in platelet aggregation assays, and reduced activity under physiologic shear stress. In the microfluidic assay, platelet adhesion to collagen in the first 60 s was not affected (Fig. 3D) , but the binding of flowing platelets to collagen-adherent platelets was decreased, and large platelet aggregates dislodged more rapidly. These effects correlated with direct inhibiton of MERTK phosphorylation in platelets, and reduced downstream signaling through AKT and SRC (Fig. 1A,B) , implicating MERTK inhibition as a mechanism of UNC2025-mediated functional effects. Additionally, the observed decrease in signaling of SRC, a known prothrombotic mediator in platelets [45] and a downstream target of TAM kinase signaling [46] , suggests a biochemical mechanism by which TAM kinase inhibition mediates antithrombotic effects. However, a direct effect on SRC cannot be ruled out. It is of note that UNC2025 is equipotent against MERTK and FLT3, with 50-fold greater selectivity in cell-based assays than for AXL, the next most potently inhibited kinase [26] ; however, FLT3 expression has not been reported in human or murine megakaryocytes or platelets, so the effects of treatment with UNC2025 are probably not mediated by FLT3 inhibition. Treatment with UNC2025 phenocopies the effects of genetic TAM kinase deletion in mouse platelets. Specifically, platelets from Gas6 À/À and Mertk À/À mice show reduced aggregation in vitro and decreased clot stability in vivo [2] [3] [4] , which are similar to the effects of UNC2025 reported here.
The similar inhibition of activation responses observed in both human and mouse platelets validates the use of UNC2025 for translational application in mouse models of thrombosis. The increased embolization that we noted in the microfluidic flow assay and arterial thrombosis model is reminiscent of the transient rebleeding after tailclip in Mertk -/-mice noted previously [2] , and is consistent with previous observations that Gas6 -/-platelets form unstable aggregates under flow [5] . Whereas TTFO was minimally prolonged for inhibitor-treated mice, a significant difference was seen in the DOO between UNC2025-treated mice and controls. As the DOO is directly proportional to aggregate stability in this model, these results reflect relatively normal initial platelet adhesion and accumulation, but subsequent inability to stabilize aggregates in the setting of GAS6-TAM inhibition, consistent with what we observed in vitro. The results from the murine intravital laser-induced microvascular injury model demonstrated that GAS6-TAM inhibition decreases accumulation of activated (P-selectin-positive) platelets at injury sites by affecting platelet-platelet interactions, but not initial platelet adhesion or fibrin accumulation (a surrogate for thrombin activity). When considered in the context of hierarchical clot organization [40] , these data suggest that GAS6-TAM inhibition may primarily affect the core of a newly formed clot.
Although the in vitro experiments show that UNC2025 affects platelet function (human and murine) specifically, endothelial cells also express TAM receptors, and we cannot rule out a vascular effect of the compound in vivo. Future studies using transgenic models and transfused platelets will further elucidate any contribution of the vasculature to the observed phenotype. UNC2025 also mediated a synergistic decrease in platelet aggregation in combination with an inhibitor of the ADP receptors P2Y 1 and P2Y 12 (P2Yi). This effect was recapitulated in vivo in the FeCl 3 -induced arterial and PE thrombosis models, in which the addition of UNC2025 allowed for a 50% reduction in P2Yi dose without compromising thrombosis protection, consistent with prior evidence of synergy between GAS6-evoked and ADP receptor inhibitor-evoked AKT phosphorylation [5] . Interestingly, inhibition of platelet aggregation and degranulation by MERTK antagonism can be overcome by high concentrations of ADP or thrombin receptor agonist peptide [6] , and coinfusion of ADP can overcome the reduced aggregate formation under flow in Gas6
Axl À/À mice [5] , suggesting complementary roles for ADP-P2Y and GAS6-TAM signaling. Thus, combined GAS6-TAM and ADP-P2Y signaling is expected to mediate more effective inhibition of common downstream pathways, such as AKT and b 3 integrin, and our data support the idea that addition of a GAS6-TAM inhibitor to P2Yi treatment regimens could allow for P2Yi dose reduction, leading to a decreased risk of concomitant bleeding while maintaining the antithrombotic effect of HD P2Yi therapy [47, 48] . In addition, owing to the moderate inhibition of platelet activation caused by UNC2025, GAS6-TAM inhibitors may be most useful as an adjunct to standard antiplatelet therapy, in a role similar to that considered for antithrombotic agents such as the protease-activated receptor 1 antagonist vorapaxar [49] [50] [51] or protein disulfide isomerase inhibitors [52] . Treatment with UNC2025 has been well tolerated in mice for up to 150 days, and the primary side effects associated with HD UNC2025 treatment were anemia and leukopenia [28] . These effects were not dose-limiting, and were probably primarily attributable to FLT3 inhibition in the bone marrow compartment. More extensive studies to assess the impact of MERTK inhibition on inflammation, infection and autoimmunity are needed to assess the potential consequences of long-term treatment with UNC2025.
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